Glioma Tumor Stem-Like Cells Promote Tumor Angiogenesis and Vasculogenesis via Vascular Endothelial Growth Factor and Stromal-Derived Factor 1

Chris Folkins,1,2 Yuval Shaked,3 Shan Man,1 Terence Tang,1 Christina R. Lee,1 Zhenping Zhu,4 Robert M. Hoffman,5 and Robert S. Kerbel1,2

1Department of Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, and Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; 2Technion-Israel Institute of Technology, Haifa, Israel; 3ImClone Systems, New York, New York; and 4AntiCancer, Inc., San Diego, California

Abstract

Cancer stem cells (CSC) are predicted to be critical drivers of tumor progression due to their self-renewal capacity and limitless proliferative potential. An emerging area of research suggests that CSC may also support tumor progression by promoting tumor angiogenesis. To investigate how CSC contribute to tumor vascular development, we used an approach comparing tumor xenografts of the C6 glioma cell line containing either a low or a high fraction of CSC. Compared with CSC-low tumors, CSC-high tumors exhibited increased microvessel density and blood perfusion and induced increased mobilization and tumor recruitment of bone marrow–derived endothelial progenitor cells (EPC). CSC-high C6 cell cultures also induced higher levels of endothelial cell proliferation and tubule organization in vitro compared with CSC-low cultures. CSC-high cultures and tumors expressed increased levels of the proangiogenic factors vascular endothelial growth factor and stromal-derived factor 1, and when signaling by either factor was blocked, all aspects of angiogenesis observed in CSC-high cultures and tumors, including microvessel density, perfusion, EPC mobilization/recruitment, and stimulation of endothelial cell activity, were reduced to levels comparable with those observed in CSC-low cultures/tumors. These results suggest that CSC contribute to tumor angiogenesis by promoting both local endothelial cell activity and systemic angiogenic processes involving bone marrow–derived EPC in a vascular endothelial growth factor–dependent and stromal-derived factor 1–dependent manner. [Cancer Res 2009;69(18):7243–51]

Introduction

Significant progress has been made in identifying stem cell-like fractions of tumor cells in a wide variety of human cancers, and characterizing their key properties, which include high tumor-initiating potential, self-renewal, and multilineage differentiation capabilities, and the expression of "stemness" pathways involved in the maintenance of these properties (1). The features of the cancer stem cell (CSC) fraction suggest that they may be critical in sustaining tumor progression, and it is therefore increasingly important to further our understanding of this unique cell population and how it affects tumor biology. In this regard, an emerging area of research suggests that CSC, in addition to their proliferative capabilities, may have a role in promoting tumor angiogenesis.

A study by Bao and colleagues (2) found that the CSC-enriched CD133+ fraction of human glioma cells had a significantly stronger capacity to promote angiogenesis than the CSC-depleted CD133− fraction. CD133+ cells consistently yielded aggressive, highly vascularized tumors when implanted in mice, whereas CD133− cells were rarely tumorigenic and gave rise to tiny, poorly vascularized tumors. The proangiogenic capacity of the CD133+ fraction was attributable to vascular endothelial growth factor (VEGF) activity. Other studies are consistent with the results of Bao and colleagues and further suggest a proangiogenic role for CSC. For example, CD133+ CSC from the U87 human glioblastoma cell line expressed more VEGF and gave rise to more angiogenic xenograft tumors compared with their CD133−, non-stem-like counterparts (3). CSC-enriched spheroid cultures of the MCF7 human breast cancer cell line have also been reported to express more VEGF than matched monolayer cultures with a lower CSC fraction (4). Similarly, CSC-enriched neurospheres derived from the GL261 murine glioma cell line express more VEGF and display a more proangiogenic expression signature based on microarray analysis compared with adherent, CSC-low GL261 cultures (5).

Tumor vascular development is a multifactorial process, incorporating both sprouting angiogenesis, in which tumor-derived factors promote nascent capillary formation by endothelial cells in the local tumor microenvironment, and adult vasculogenesis, in which bone marrow–derived endothelial progenitor cells (EPC) home to the tumor site, differentiate into mature endothelial cells, and incorporate into growing tumor vessels (6–13). Additionally, several other bone marrow–derived cell (BMDC) types can be recruited to sites of active angiogenesis, where they may promote angiogenesis in a paracrine manner (6, 14–19). To gain a more thorough understanding of how CSC contribute to blood vessel growth in tumors, we investigated how the stem-like cell fraction from the rat C6 glioma cell line influences tumor angiogenesis, endothelial cell organization and proliferation, and mobilization and recruitment of BMDC.

Materials and Methods

Cell culture. C6 (American Type Culture Collection) were maintained as monolayers [CSC-low, serum-containing (Ser+) condition] or nonadherent tumor spheres [CSC-high, serum-free supplemented (SFS) condition] as described (20). Human umbilical vein endothelial cells (HUVEC; Cambrex...
Bioscience Walkersville) were maintained as described (21). Adherent cells were harvested with 0.25% trypsin-0.03% EDTA (Invitrogen), and tumor spheres were dissociated by mechanical trituration.

Mice and xenografts. For most experiments, 6- to 8-week-old female athymic nude mice (Harlan) were injected s.c. with 2 \times 10^6 C6 cells in 200 \mu L serum-free DMEM.

Tumor sphere-forming assay. Tumor sphere-forming assay was done as described (21).

Limiting dilution tumor initiation assay. Nude mice were injected with 100, 1000, 5000, 10,000, or 50,000 C6 cells. Mice were monitored for 3 months and scored as positive (palpable tumor) or negative.

Immunofluorescent staining of cytospins and tumor sections. For cytospins, 100,000 cells in DMEM + 10% fetal bovine serum were loaded in 200 \mu L MCH. Cells/tissues were fixed in 4% paraformaldehyde and blocked with 10% goat serum. Antibodies were diluted in DAKO antibody diluent, and incubations were done at room temperature. Where indicated, cells/tissues were counterstained with 1 \mu g/mL 4',6-diamidino-2-phenylindole (Molecular Probes). Images were acquired using a Zeiss Axioplan II with Zeiss Axiocam and Axio Vision 4.6.3 software and analyzed using Adobe Photoshop 6.0.

Antibodies. Antibodies used include purified mouse anti-rat nestin (1:100; BD Biosciences) with Texas red-conjugated goat anti-rabbit secondary (1:200; Jackson ImmunoResearch Laboratories), rat anti-mouse CD31 (1:100; BD Biosciences) with Cy3-donkey anti-rat secondary (1:200; Jackson ImmunoResearch Laboratories), and rabbit polyclonal anti-VEGF receptor (VEGFR) 2 antibody (ref. 23; ImClone Systems). HUVEC were incubated with 100 \mu L/well conditioned medium ± drug at 37°C for 18 h, after which cells were pulsed with 2 \mu Ci [3H]thymidine for 6 h. Endothelial cell proliferation assays. HUVEC were plated at 3,000 per well in 200 \mu L DMEM medium in 1% gelatin-coated 96-well microplates and allowed to attach overnight. C6 conditioned medium was supplemented with 10 units/mL heparin, and aliquots were supplemented with 1,000 \mu M AMD3100, a small-molecule antagonist of the SDF1 receptor CXCR4 (ref. 22; Sigma), or 100 \mu g/mL IMC1121-b, a monoclonal anti-human VEGF receptor (VEGFR) 2 antibody (ref. 23; Immuno-Biological Laboratories). HUVEC were incubated with 100 \mu L/well conditioned medium ± drug at 37°C for 18 h, after which culture medium was harvested and spun down, and supernatants were stored at −80°C.

Endothelial cell tubule formation assays. C6 conditioned medium was supplemented with 10 units/mL heparin and 10% fetal bovine serum, and aliquots were supplemented with 200 \mu M AMD3100 or 100 \mu M IMC1121-b. HUVEC were suspended in conditioned medium ± drug at 100,000/mL, and 300 \mu L/well were plated on Matrigel-coated Lab-Tek II 8-well chamber slides (Nunc) and incubated at 37°C for 20 h. Images were acquired using a Zeiss Axioplan 2 (bright-field, \times 100) with attached Zeiss Axiocam and Axio Vision 4.6.3 software, and tubule length was measured using Image 1 analysis software (NIH).

ELISA and Western blotting. Conditioned medium was analyzed undiluted using Quantikine mouse VEGF ELISA kit (R&D Systems) according to the manufacturer’s instructions. For Western blotting, whole-cell lysates were prepared as described (24). Proteins from conditioned medium samples were precipitated by mixing 1 mL ± 5 mL with methanol and incubating for 1 h at −80°C, pelleted, and dried. Western blotting done as described (24).

Bone marrow reconstitution. Bone marrow cells harvested from femurs of athymic nude-green fluorescent protein (GFP) mice (ref. 25; Fig. 4C and D; AntiCancer) or UBI-GFP/BL6 mice (Figs. 4B and C and 6C; The Jackson Laboratory) were injected into the tail veins of lethally

Generation of C6 conditioned medium. C6 cells were plated in DMEM + 2% fetal bovine serum at 1.25 \times 10^6/mL and incubated at 37°C. After 24 h, culture medium was harvested and spun down, and supernatants were stored at −80°C.

Endothelial cell proliferation assays. HUVEC were plated at 3,000 per well in 200 \mu L DMEM medium in 1% gelatin-coated 96-well microplates and allowed to attach overnight. C6 conditioned medium was supplemented with 10 units/mL heparin, and aliquots were supplemented with 1,000 \mu M AMD3100, a small-molecule antagonist of the SDF1 receptor CXCR4 (ref. 22; Sigma), or 100 \mu g/mL IMC1121-b, a monoclonal anti-human VEGF receptor (VEGFR) 2 antibody (ref. 23; Immuno-Biological Laboratories). HUVEC were incubated with 100 \mu L/well conditioned medium ± drug at 37°C for 18 h, after which cells were pulsed with 2 \mu Ci [3H]thymidine for 6 h. Endothelial cell tubule formation assays. C6 conditioned medium was supplemented with 10 units/mL heparin and 10% fetal bovine serum, and aliquots were supplemented with 200 \mu M AMD3100 or 100 \mu M IMC1121-b. HUVEC were suspended in conditioned medium ± drug at 100,000/mL, and 300 \mu L/well were plated on Matrigel-coated Lab-Tek II 8-well chamber slides (Nunc) and incubated at 37°C for 20 h. Images were acquired using a Zeiss Axioplan 2 (bright-field, \times 100) with attached Zeiss Axiocam and Axio Vision 4.6.3 software, and tubule length was measured using Image 1 analysis software (NIH).

ELISA and Western blotting. Conditioned medium was analyzed undiluted using Quantikine mouse VEGF ELISA kit (R&D Systems) according to the manufacturer’s instructions. For Western blotting, whole-cell lysates were prepared as described (24). Proteins from conditioned medium samples were precipitated by mixing 1 mL ± 5 mL with methanol and incubating for 1 h at −80°C, pelleted, and dried. Western blotting done as described (24).

Bone marrow reconstitution. Bone marrow cells harvested from femurs of athymic nude-green fluorescent protein (GFP) mice (ref. 25; Fig. 4C and D; AntiCancer) or UBI-GFP/BL6 mice (Figs. 4B and C and 6C; The Jackson Laboratory) were injected into the tail veins of lethally
irradiated (900 rads), 6- to 8-week-old female athymic nude mice (Harlan; 10^7 cells per mouse). Mice were used in subsequent experiments after 8 weeks to allow for reconstitution.

**Visualization of tumor vessel–associated BMDC.** Sections of tumors grown in GFP bone marrow–reconstituted mice were stained for CD31 as above and visualized using a Zeiss Axiovert 100 with LSM510 confocal imaging system and Zeiss Advanced Imaging Microscopy software.

**Flow cytometry.** Circulating EPC were evaluated using flow cytometry as described (26). For analysis of tumor-recruited BMDC, single-cell suspensions were prepared as above. Cells were stained according to the antibody manufacturer’s instructions. Tumor-recruited bone marrow–derived endothelial cells were defined as GFP+/VEGFR2+/CD31+/CD45−, recruited bone marrow–derived circulating cells (RBCC)/hemangiocytes as CXCR4+/CD11b+/VEGFR1+/CD45+, and Tie2-expressing monocytes (TEM) as Tie2+/CD11b+/VEGFR1+/CD45+. At least 50,000 events per sample were acquired, and at least 100 events were acquired in the final gate of each experiment. All antibodies were purchased from BD Biosciences.

**VEGF and SDF1 blocking experiments in vivo.** Mice with palpable C6 tumors (7-12 days post-implantation) were treated for 2 weeks with the anti-mouse VEGFR2 blocking monoclonal antibody DC101 (ref. 27; ImClone Systems; in PBS, 800 μg/mouse/3 days i.p.) or AMD3100 (in PBS, 5 mg/kg/d s.c.). Control animals received PBS.

**Statistical analysis.** Histograms represent mean ± SE. Asterisks in figures denote analysis versus matched CSC-low groups (Student’s t test): ***, P < 0.001; **, P < 0.01; *, P < 0.05.

### Results

C6 tumor sphere cultures are enriched in CSC and give rise to CSC-enriched xenograft tumors. Previous studies on the proangiogenic nature of CSC, such as the one by Bao and colleagues (2), have compared fluorescence-activated cell sorting–sorted CSC and non-CSC populations. One difficulty with this approach is that, as Bao and colleagues reported, the non-CSC population rarely gives rise to tumors, and when it does, they are extremely growth-limited and poorly vascularized. Although in this situation it is tempting to conclude that the non-CSC-derived tumors are poorly vascularized due to lack of angiogenic capacity in the non-CSC fraction, it is also possible that, due to its inherent lack of proliferative potential, the non-CSC fraction failed to drive tumor growth to a point where the angiogenic switch was initiated. To avoid such difficulties in the interpretation of our results, we used an approach comparing the angiogenic properties of size-matched, progressively growing tumors with either low or high CSC content to study how the CSC fraction influences tumor vascular development.

The C6 rat glioma cell line contains a CSC fraction that can be expanded by prolonged culture in serum-free medium (20). We took advantage of this property and generated long-term C6 cultures grown either as monolayers in serum-containing media (Ser+ condition) or as nonadherent tumor spheres in serum-free medium (SFS condition) supplemented as described (20). Consistent with the results of Kondo and colleagues (20), our C6 SFS cultures were significantly enriched in CSC compared with the C6 Ser+ cultures as evidenced by increased formation of tumor spheres at clonal density in serum-free conditions (Fig. 1A), increased expression of the neural precursor marker nestin (Fig. 1B), and increased tumor-initiating capacity when implanted.

<table>
<thead>
<tr>
<th>No. C6 cells injected</th>
<th>Tumor take (sites engrafted/injected)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Injecting Ser+</td>
<td>Injecting SFS</td>
</tr>
<tr>
<td>50,000</td>
<td>10/10</td>
</tr>
<tr>
<td>10,000</td>
<td>10/10</td>
</tr>
<tr>
<td>5,000</td>
<td>3/10</td>
</tr>
<tr>
<td>1,000</td>
<td>0/10</td>
</tr>
<tr>
<td>100</td>
<td>0/10</td>
</tr>
</tbody>
</table>

**Table 1. Limiting dilution tumor initiation assay**

NOTE: Five mice per dilution, right and left flanks were injected, for a total of 10 injections per dilution. Results at 5,000 cell dilution are significantly different (P = 0.0198, Fisher’s exact test).

![Figure 2. Microvessel density and blood perfusion in CSC-low and CSC-high tumors. A. top, CD31+ microvessels (Cy3; red), ×200; bottom, blood perfusion (Hoechst; blue), ×100. B, image quantification of microvessel density: number of CD31+ (red) structures per field (counted manually). C, image quantification of blood perfusion: total Hoechst fluorescence intensity (total colored pixels × mean fluorescence intensity) per field. Five mice per group, five fields analyzed per tumor.](#)
s.c. in nude mice at limiting dilution (Table 1). The difference in tumor-initiating capacity was only noticeable when 5,000 cells were injected. A possible explanation for this is that, at the next highest dilution (10,000 cells), there is a sufficient number of tumorigenic cells in both groups to initiate a tumor and, at the next lowest dilution (1,000 cells), there is an insufficient number of tumorigenic cells in either group. Another possible contributing factor is that, at the lowest dilutions in our assay, the likelihood that sufficient numbers of tumorigenic cells remain healthy throughout the xenotransplant process and retain their ability for tumor "take" is reduced. Ser− and SFS-derived tumors grew at similar rates when 5,000 or 10,000 cells were injected, although, when 50,000 cells were injected, the growth rate of Ser−-derived tumors was somewhat faster, and this difference was statistically significant (Supplementary Fig. S1). This difference in growth rate may be reflective of the slower cycling time associated with stem-like cells.

After 4 weeks of tumor growth, cells from dissociated SFS-derived tumors still formed significantly more tumor spheres at clonal density than cells from Ser+-derived tumors (Fig. 1C), indicating that CSC-low (Ser+) and CSC-high (SFS) cultures give rise, respectively, to tumors that maintain a sustained low or high fraction of self-renewing CSC.

Tumor volume matching. To account for the noted difference in growth rate, in each subsequent in vivo experiment where CSC-low and CSC-high tumors are compared, tumors were selected such that the average tumor volume between groups was not significantly different.

Increased vessel density and blood perfusion in CSC-high tumors. To determine the effect of the CSC fraction on tumor angiogenesis, Ser+ or SFS cells were implanted s.c. in nude mice. After 3 weeks, tumor microvessel density and blood perfusion were assessed. Both microvessel density (Fig. 2A, top, b) and perfusion (Fig. 2A, bottom, c) were significantly higher in CSC-high tumors, suggesting that the CSC fraction has a role in promoting tumor vascular development.

Increased promotion of endothelial cell proliferation and tubule formation by CSC-high cultures. To gain insight into the mechanisms underlying the increased angiogenesis observed in CSC-high tumors, we investigated the effects of secreted factors from CSC-low and CSC-high C6 cultures on vascular endothelial cells in vitro. HUVEC were plated with either CSC-low or CSC-high conditioned medium, and proliferation was measured by radiolabeled thymidine incorporation assay. Similarly, HUVEC were plated on Matrigel with C6 conditioned medium to assess formation of capillary-like tubule networks. Higher degrees of both endothelial cell proliferation (Fig. 3A and B) and tubule formation (Fig. 3C) were promoted by CSC-high conditioned medium, suggesting that CSC may promote angiogenesis in part by stimulation of endothelial cell activity.

Increased endothelial progenitor mobilization and BMDC recruitment in mice with CSC-high xenograft tumors. Another contributing factor to tumor vascular development is the recruitment of various proangiogenic BMDC populations in mice bearing CSC-low or CSC-high tumors.

Mice with CSC-high tumors had significantly higher levels of circulating EPC than mice with CSC-low tumors (Fig. 4A; Supplementary Fig. S2), suggesting a role for CSC in mobilizing EPC. To evaluate and visualize BMDC recruitment, lethally irradiated nude mice were reconstituted with bone marrow from GFP+ donors and implanted with CSC-low or CSC-high tumors. Tumor sections were stained with a fluorescent-tagged antibody to the vascular marker CD31, and vessel-associated BMDC (GFP+ cells within CD31+ microvessels) were visualized by confocal microscopy. The fraction of microvessels with associated BMDC was not significantly different between CSC-low and CSC-high tumors.
With this methodology, we are potentially visualizing several different BMDC populations simultaneously, which may mask significant differences in recruitment of specific BMDC subpopulations between CSC-low and CSC-high tumors. Therefore, we employed a second approach to evaluate recruitment of specific BMDC subpopulations.

To evaluate recruitment of EPC, RBCC/hemangiocytes, and TEM, flow cytometry was used on dissociated tumors from GFP-bone marrow–reconstituted mice to identify BMDC (GFP+) in the tumor expressing endothelial cell markers (VEGFR2+/CD31+/CD45− to identify recruited, matured EPC) or markers for RBCC/hemangiocytes (CXCR4+/CD11b−/VEGFR1+/CD45−) or TEM (Tie2+/CD11b+/VEGFR1+/CD45−). There was no significant difference in recruitment of RBCC/hemangiocytes or TEM between CSC-low and CSC-high tumors (Fig. 4C), whereas significantly higher numbers of GFP+ endothelial cells were recruited to CSC-high tumors (Fig. 4D). This suggests that CSC promote homing and recruitment of EPC to the tumor. The possibility remains that CSC contribute to recruitment of other BMDC as well, although our results suggest that in our model CSC do not significantly affect recruitment of RBCC/hemangiocytes or TEM.

Increased expression of proangiogenic factors in CSC-high cultures and tumors. To further our understanding of CSC-driven angiogenic processes, we evaluated expression of two important proangiogenic factors, VEGF and SDF1, in CSC-low and CSC-high cultures and tumors. VEGF is a potent stimulator of local angiogenesis and EPC mobilization (28), and SDF1 promotes EPC recruitment and endothelial cell activity (29–31). Furthermore, we recently found that chemotherapy induces EPC mobilization mediated by systemic SDF1 induction (32). ELISA using conditioned medium showed that more VEGF was secreted by CSC-high cultures (Fig. 5A). SDF1 secretion was measured by Western blot of precipitated proteins from conditioned medium. Although whole-cell lysate of CSC-high cultures contained less SDF1 than CSC-low culture lysate, conditioned medium precipitate from CSC-high culture was greatly enriched for SDF1 (Fig. 5B). This suggests that, in CSC-low tumors, SDF1 is not as highly secreted, so intracellular levels are higher, whereas, in CSC-high tumors, SDF1 secretion is increased, so intracellular levels are low but extracellular levels are high. Immunofluorescent staining of established CSC-low and CSC-high tumor sections showed that CSC-high tumors express significantly more VEGF (Fig. 5C, top) and SDF1 (Fig. 5C, bottom). In immunostained tumor sections, we are likely seeing an overlap of intracellular and extracellular SDF1, which may explain why the difference in magnitude of expression is less apparent than what was observed by Western blot.

Figure 4. EPC mobilization and vessel incorporation in mice with CSC-low and CSC-high tumors. A, EPC in peripheral blood ± DC101 (#/μL blood). Five mice per group. B, vessel-associated BMDC (GFP+; green) in CD31-stained microvessels (Cy3; red; ×200). Top, full field; bottom, zoomed subsection. Bar, 50 μm. Histogram: image quantification of microvessels containing BMDC (number of GFP+, CD31+ microvessels/field divided by total number of microvessels/field; counted manually). Five mice per group, eight fields per tumor. C and D, GFP+ RBCC/hemangiocytes, TEM (C), or endothelial cells (D), per 10,000 tumor cells, assessed by flow cytometry. Mice per group: (C) 8 for CSC-low and 10 for CSC-high and (D) 5 per group.
CSC-derived VEGF and SDF1 are important mediators of CSC-driven angiogenesis. To evaluate the importance of VEGF and SDF1 in CSC-driven angiogenic processes, we performed blocking experiments using CSC-low and CSC-high cultures and tumors. When tumor-bearing mice were treated with the anti-mouse VEGFR2-blocking monoclonal antibody DC101 (Fig. 6A), or AMD3100, a small-molecule antagonist of the SDF1 receptor CXCR4 (Fig. 6B), CSC-high tumors no longer exhibited increased microvessel density compared with CSC-low tumors, suggesting that VEGF and SDF1 are important in establishing the "angiogenic advantage" observed in CSC-high tumors.

Because we found that CSC promote local endothelial cell activity and EPC recruitment, we investigated the importance of VEGF and SDF1 in each of these mechanisms of CSC-driven angiogenesis. When HUVEC were incubated with C6 conditioned medium and AMD3100 (Fig. 3B) or an anti-human VEGFR2-blocking antibody (Fig. 3A), CSC-high conditioned medium no longer stimulated increased microvessel density compared with CSC-low tumors, suggesting that VEGF and SDF1 are important in establishing the "angiogenic advantage" observed in CSC-high tumors.

DC101 dramatically reduced the increased mobilization of EPC previously observed in mice with CSC-high tumors (Fig. 4A). Similarly, AMD3100 reduced EPC recruitment in CSC-high tumors to levels similar to those in CSC-low tumors (Fig. 6C). AMD3100 had no significant effect on recruitment of RBCC/hemangiocytes or TEM (data not shown). These results suggest that VEGF and SDF1 promote CSC-driven EPC mobilization and homing/recruitment, respectively.

Discussion
The recent surge in interest in the CSC model has led to an enormous amount of research seeking to identify and characterize CSC in nearly every major disease site. This interest is largely driven by the prediction that CSC represent a critical (and previously unrecognized) therapeutic target. Specifically, the proliferative and...
self-renewal capabilities of CSC imply that they have important roles in initiating and sustaining tumor growth, and evidence also suggests a role in metastasis (1). Our work suggests that CSC may have a role in yet another critical element of tumor progression, that is, tumor angiogenesis. We show that tumors with a high CSC content are more strongly angiogenic and that this results from increased local endothelial cell activity as well as mobilization and homing/recruitment of bone marrow–derived EPC, both of which are dependent on increased expression of VEGF and SDF1. Our findings are consistent with previous studies showing increased expression of proangiogenic factors and increased stimulation of angiogenesis by the CSC fraction compared with non-CSC tumor cells (2–5). These findings highlight the need for continued investigation into CSC as a potentially important target for therapy.

It may seem counterintuitive to expect that CSC, which by definition represent a very small minority of cells in a tumor, could make a significant contribution to tumor angiogenesis. It is important to note, however, that, early during tumor initiation or the seeding of a metastatic lesion, CSC would in theory represent a much higher fraction of the overall tumor cell mass. It is in these scenarios that the effect of CSC on angiogenesis may be significant. Indeed, transient bursts of angiogenic activity can be sufficient to initiate sustained tumor angiogenesis (33). Therefore, it is possible that CSC provide the signals necessary to trip the “angiogenic switch” early during the growth of primary and/or metastatic tumors. This is an interesting possibility to consider in light of recent evidence suggesting that glioma CSC are maintained by a vascular niche (34). It is logical that, as part of its ability to initiate a primary tumor or seed a metastatic lesion at distant sites with potentially suboptimal microenvironments, a CSC has the built-in capacity to promote the development of a niche to support its survival. If further research uncovers a role for CSC in the angiogenic switch, this may inform the development of new antiangiogenic therapeutic approaches aimed at, for example, disrupting CSC-derived angiogenic “bursts” during the growth of metastatic lesions.

Another circumstance in which proangiogenic capabilities of CSC may be important is during tumor regrowth following therapy. Due to properties they share with normal tissue stem cells, CSC are predicted to be resistant to many conventional cytotoxic anticancer therapies and consequently are expected to survive following therapy and drive tumor regrowth (35). Indeed, the CSC fraction is enriched following radiotherapy (36) and chemotherapy (37). The core of resistant CSC remaining after treatment represents another scenario in which CSC would make up a significant fraction of the overall tumor mass and consequently may have a significant role in supporting tumor regrowth by reinitiating angiogenesis. This concept is particularly interesting when considered in the context of recent studies from our group.

We have found that, following treatment with cytotoxic agents including standard chemotherapy drugs (32) and vascular-disrupting agents (38), host-mediated systemic mobilization of EPC from the bone marrow occurs, resulting in angiogenic rebound and tumor cell repopulation. Considering the drug resistance and proangiogenic properties of CSC, it is reasonable to predict that they contribute to this observed rebound following cytotoxic therapy. Furthermore, this angiogenic rebound and associated tumor regrowth was blunted by combining antiangiogenic agents with the cytotoxic treatments (32, 38). The possibility that drug-resistant CSC contribute to the rebound process underscores the importance of using this type of combination treatment approach because multiple cycles of cytotoxic therapy would be predicted to gradually enrich the proangiogenic CSC fraction in the tumor, thereby enhancing blood vessel regrowth and tumor repopulation in the absence of a coadministered antiangiogenic agent. Following similar reasoning, one could predict that tumors with an inherently larger CSC fraction would promote a more robust vascular rebound/repopulation, making the use of antiangiogenic/cytotoxic combination therapies particularly important with such tumors. If these concepts are valid, they could inform treatment decisions in the future if it becomes possible to assess the CSC fraction a priori and possibly the development of new therapeutic strategies, such as the addition of CSC-targeted therapies to cytotoxic/antiangiogenic combination regimens to further blunt CSC-derived proangiogenic signaling.

Our work may have additional implications for our understanding of the contribution of bone marrow–derived EPC to tumor

---

**Figure 6.** VEGF- and SDF1-blocking experiments in mice with CSC-low and CSC-high tumors. A and B, image quantification of microvessel density in tumors ± DC101 (anti-VEGFR2) or AMD3100: number of CD31+ structures per field (counted manually). Five mice per group, eight fields per tumor. C, quantification of vessel-associated, bone marrow–derived (GFP+) endothelial cells (CD31+/VEGFR2+/CD45+) ± AMD3100 per 10,000 tumor cells by flow cytometry. Five mice per group, except CSC-low control (n = 3).
vascular development. Many studies have suggested that EPC residing in the bone marrow can be recruited to the tumor in response to tumor-derived cytokines, where they contribute to vascular development by incorporating into the walls of nascent capillaries (6). The significance of this contribution is still a matter of considerable debate, however. Although some studies have shown a significant role for EPC in tumor angiogenesis in certain models (7–13), and previous work from our group has shown that a robust recruitment of these cells occurs following cytotoxic therapy (32, 38), in many cases, the level of EPC incorporation into tumor vessels is reported to be very low or even nonexistent (39–45), calling into question the general relevance of these cells to tumor blood vessel growth. Our work suggests that tumors with a larger CSC fraction recruit greater numbers of EPC, which raises the possibility that EPC recruitment may play a more significant role in tumor vascular development in tumors with a large CSC fraction. The correlation between CSC fraction and EPC recruitment could possibly explain some of the discrepancies in the observed levels of EPC recruitment between various studies, because the size of the CSC fraction is also reported to vary significantly between different tumor types as well as between individuals with the same tumor type (1). Further study of the relationship between CSC and EPC is warranted, as both of these cell types, although currently incompletely understood, have potentially major implications for tumor biology and therapy.

Significant work is required before we can fully understand the role of the CSC fraction in tumor angiogenesis. It will be important to study the mechanisms, timing, and extent of involvement of CSC in the various angiogenic processes, as these will all have implications for our understanding of tumor vascular development and CSC biology as well as our approach to various anticancer therapies including antiangiogenic and CSC-targeted therapies. As with many aspects of CSC biology, however, advancement in this area will depend primarily on the continued development of better models and improved techniques to better identify, isolate, and track CSC throughout tumor development.

Disclosure of Potential Conflicts of Interest

R.M. Hoffman: Chief Executive Officer of AntiCancer, Inc. The other authors disclosed no potential conflicts of interest.

Acknowledgments

Supported by grants from the National Cancer Institute (R01 CA110204, P01 CA062924, and R01 CA097040), a grant from Stand Up To Cancer, and grants from Parks/Calabasas and the Wallace Foundation. R.M. Hoffman: Chief Executive Officer of AntiCancer, Inc. The other authors disclosed no potential conflicts of interest.

References


